2025年上半年商业销售总额达3.098亿元。其中，佳泰莱® 的销售占97.6%。同时，药品销售的所有应收 账款均于账期内收回，资金回笼高效稳健。 在三个具备ADC及新型偶联药物、大分子(单抗及双抗)以及小分子药物专有技术、内部开发的技术平台 的支援下，并经我们的临床阶段候选药物验证，我们的管线在药物模态、机制及适应症覆盖范围方面具 有多样性，并在这些方面发挥协同效应。值得注意的是，我们是开发ADC的先行者之一，在ADC开发 方面积累了超过十年的经验。我们是中国首批也是全球为数不多的建立内部开发ADC及新型偶联药物 平台OptiDCTM的生物制药公司之一。我们符合cGMP标准的端到端制造能力及全面的质量管理体系进 一步支援我们的药物开发能力。此外，凭藉我们控股股东科伦药业数十年的经验、行业关系及广泛的网 络，我们具备了扩充商业化基础设施及市场管道的良好条件。 智通财经APP讯，科伦博泰生物-B(06990)发布截至2025年6月30日止6个月的中期业绩，该集团取得收入 人民币9.5亿元(单位下同)，同比减少31.3%;研发开支6.12亿元，同比减少6.3%;公司权益股东应占亏损 1.45亿元;每股亏损0.64 ...

Core Insights - The company reported a revenue of RMB 950 million for the six months ending June 30, 2025, representing a year-on-year decrease of 31.3% [1] - Research and development expenses amounted to RMB 612 million, down 6.3% year-on-year [1] - The company incurred a loss attributable to equity shareholders of RMB 145 million, with a loss per share of RMB 0.64 [1] Financial Performance - Total commercial sales for the first half of 2025 reached RMB 309.8 million, with 97.6% of sales coming from the product "佳泰莱" [1] - All accounts receivable from drug sales were collected within the payment period, indicating efficient cash flow management [1] Product Development and Pipeline - The company has received marketing approvals for sac-TMT (佳泰莱), Tagolizumab (科泰莱), and Cetuximab N01 (达泰莱) and has commenced commercialization [1] - The company anticipates launching "博度曲妥珠单抗" (舒泰莱) in the Chinese market in the second half of 2025, pending regulatory communication and approval [1] - The company is a pioneer in developing ADCs and has over ten years of experience in this field, with a proprietary platform for ADC and novel conjugated drugs [2] Manufacturing and Quality Management - The company possesses end-to-end manufacturing capabilities that comply with cGMP standards and a comprehensive quality management system to support drug development [2] - The company benefits from the extensive experience, industry relationships, and network of its controlling shareholder, 科伦药业 (002422), which enhances its commercialization infrastructure and market pipeline [2]